Science and Enterprise

Tag: biotechnology

  • Cleantech, Electronics Venture Funding Jump in 2010

    Venture capital investments recorded a solid increase in 2010 over 2009, the first annual jump since 2007. Industries based on science and engineering were among the gainers, particularly clean technology and electronics. The statistics were contained in the MoneyTree Report by PricewaterhouseCoopers and the National Venture Capital Association (NVCA), based on data from Thomson Reuters.…

  • Theraclone, Pfizer to Partner on Antibody R&D

    Theraclone Sciences Inc., a drug discovery and development company in Seattle, Washington, said today it agreed to a multi-year research and development collaboration with the global pharmaceutical company Pfizer. The deal involves use of Theraclone’s I-STAR technology to discover monoclonal antibodies against up to four targets in the areas of infectious disease and cancer. The…

  • Patent Granted for Lung Disorder Treatment

    Discovery Laboratories Inc., a biotechnology company in Warrington, Pennsylvania, said today the company received a U.S. patent for its treatment of pulmonary inflammation. The patent — number 7,863,241 — expires in 2023. Discovery Labs says the patent covers its KL4 peptide (also known as sinapultide), an engineered pulmonary surfactant that lowers surface tension and promote…

  • Pharma Company, Institute Seek Alzheimer’s Targets

    Sanford-Burnham Medical Research Institute in La Jolla, California and Ortho-McNeil-Janssen Pharmaceuticals Inc. (OMJPI) in Titusville, New Jersey said today they formed a partnership to discover compounds for Alzheimer’s disease and other psychiatric disorders. Under the agreement, joint Sanford-Burnham and OMJPI teams will identify and validate new targets for drug discovery, leading to compounds suitable for…

  • Danish Pharma Company Restructures, Cuts Workforce

    NeuroSearch, a biopharmaceutical company in Copenhagen, Denmark said today the company would restructure its operations to focus more on developing drugs for the central nervous system. This reorganization of the enterprise, says NeuroSearch, will lead to a 20 percent reduction in its workforce. The goal of the restructuring is to accelerate development of its lead…

  • Nanotech Helps Reduce Cancer Drug Side Effects

    Researchers at MIT in Cambridge, Massachusetts and Brigham and Women’s Hospital in Boston have shown that they can use nanotechnology to deliver the cancer drug cisplatin much more effectively and safely. Cisplatin (illustrated right) has been approved by the FDA as a treatment alone for bladder and ovarian cancer, and with other therapies for a…

  • Consortium to Develop Sanfilippo B Gene Therapy

    Amsterdam Molecular Therapeutics (AMT), a biopharmaceuticalcompany in the Netherlands, and a group of French research institutes, including the Institut Pasteur in Paris, has formed a consortium to develop a gene therapy to treat Sanfilippo B. AMT will manufacture compounds to be tested in a clinical trial of the therapy. Sanfilippo B is a rare genetic…

  • Bristol-Myers Squibb, Biotech Partner on Alzheimer’s Test

    Opko Health Inc., a biotechnology company in Miami, Florida, said today it has a collaboration agreement with the drug manufacturer Bristol-Myers Squibb Company for Opko’s diagnostic test technology. Opko’s blood tests are being developed from its technology that identifies biomarkers for a range of diseases including neurodegenerative disorders. Part of the project calls for Opko…

  • Myeloma Foundation Awards Biotech Research Grants

    The Multiple Myeloma Research Foundation (MMRF) in Norwalk, Connecticut today announced awards of $1 million to each of three Massachusetts biotech companies through its 2010 Biotech Investment Awards program: Constellation Pharmaceuticals Inc., Epizyme Inc., and Karyopharm Therapeutics Inc. Since the biotech program began in 2006, MMRF funded research at 11 companies leading to treatments for…

  • Spirogen, Genentech Partner on Anti-Cancer Therapies

    Spirogen Ltd. a London, U.K. biotechnology company, announced a multi-year research collaboration and license agreement with Genentech, a Roche Group company, to discover and develop antibody drug conjugates (ADCs) as potential anti-cancer agents. The collaboration will make use of Spirogen’s pyrrolobenzodiazepine (PBD) drugs,  a group of natural antibiotics, and associated linking technology. Under the agreement,…